Can GLP-1 medications cause permanent gastroparesis
The SURMOUNT-1 trial compared tirzepatide at 5mg, 10mg, and 15mg doses against placebo in adults with obesity
There is a necessity to further improve carrier design and adopt rational research strategies, aiming to develop more DDS based on PTT (Zhao et al., 2022b), electrodynamic therapy (Qiao et al., 2022), radiodynamic therapy (Matsuyama et al., 2022), magnetic hyperthermia (Vangijzegem et al., 2023), immunotherapy (Lu et al., 2024), and gene nanotherapy ( While ORI faces certain challenges in drug development, its therapeutic potential remains significant
Afterwards, the IV can deliver nutrients and hydration precisely when your body is in a responsive, uptake-ready state
Total and reduced/oxidized forms of coenzyme Q10 in fibroblasts of patients with mitochondrial disease
10.1155/2022/4491900 J Diabetes Res